MX2016005687A - Metodos para potenciar la terapia inmunosupresora mediante administracion multiple de polipeptido de union a tcr alfa beta. - Google Patents

Metodos para potenciar la terapia inmunosupresora mediante administracion multiple de polipeptido de union a tcr alfa beta.

Info

Publication number
MX2016005687A
MX2016005687A MX2016005687A MX2016005687A MX2016005687A MX 2016005687 A MX2016005687 A MX 2016005687A MX 2016005687 A MX2016005687 A MX 2016005687A MX 2016005687 A MX2016005687 A MX 2016005687A MX 2016005687 A MX2016005687 A MX 2016005687A
Authority
MX
Mexico
Prior art keywords
methods
tcr
immunosuppressive therapy
beta
humanized
Prior art date
Application number
MX2016005687A
Other languages
English (en)
Other versions
MX384246B (es
Inventor
Menrad Andreas
Lacorcia Gina
Blank Gregor
Handgretinger Rupert
Schilbach Karin
Snell Daniel
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2016005687A publication Critical patent/MX2016005687A/es
Publication of MX384246B publication Critical patent/MX384246B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción está relacionada con métodos mejorados para uso de un polipéptido de unión humanizado específico para el receptor de linfocitos T alfa beta (aß-TCR). En particular, esta descripción está relacionada con métodos mejorados de uso de un anticuerpo anti-aß-TCR humanizado, que deriva del anticuerpo monoclonal murino BMA031, en terapia inmunosupresora. También se proporcionan métodos nuevos usando anticuerpos monoclonales humanizados y/o fragmentos de anticuerpo monoclonal humanizado (por ejemplo, anticuerpos anti-aßTCR y/o fragmentos de los mismos). Se proporcionan métodos nuevos que usan administración repetida de anticuerpos monoclonales humanizados y/o fragmentos de anticuerpos monoclonales humanizados (por ejemplo, anticuerpos anti-aßTCR y/o fragmentos de los mismos) para reducir linfocitos T aß en el sujeto en relación con linfocitos T yd en el sujeto.
MX2016005687A 2013-10-30 2014-10-30 POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß. MX384246B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361897809P 2013-10-30 2013-10-30
PCT/US2014/063254 WO2015066379A2 (en) 2013-10-30 2014-10-30 Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide

Publications (2)

Publication Number Publication Date
MX2016005687A true MX2016005687A (es) 2017-03-30
MX384246B MX384246B (es) 2025-03-14

Family

ID=52021413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005687A MX384246B (es) 2013-10-30 2014-10-30 POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß.

Country Status (8)

Country Link
US (2) US11142575B2 (es)
EP (1) EP3063174B1 (es)
CN (1) CN106795220A (es)
AU (2) AU2014342182B2 (es)
CA (1) CA2928756A1 (es)
MX (1) MX384246B (es)
SG (2) SG10201803473WA (es)
WO (1) WO2015066379A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX384246B (es) * 2013-10-30 2025-03-14 Genzyme Corp POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß.
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
WO2017049159A1 (en) * 2015-09-16 2017-03-23 Ledebur Jr Harry C T-CELL RECEPTOR (TCR) TARGETING THERAPIES FOR IMMUNE-MEDIATED ADVERSE DRUG REACTIONS (ADRs) AND OTHER CONDITIONS
CN108070644B (zh) * 2016-11-08 2021-06-29 国家卫生计生委科学技术研究所 一种妊娠高血压的诊断系统
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
IL271837B2 (en) * 2017-07-07 2024-01-01 Hanmi Pharm Ind Co Ltd Novel therapeutic enzyme fusion protein and use thereof
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
DE102017127984B4 (de) * 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
GB2607452B (en) * 2019-11-14 2024-06-05 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
EP4084823A4 (en) * 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
EP4263609A1 (en) 2020-12-17 2023-10-25 F. Hoffmann-La Roche AG Anti-hla-g antibodies and use thereof
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy
CN118108842A (zh) * 2023-06-09 2024-05-31 浙江大学 人源化抗cd24抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20050058641A1 (en) * 2002-05-22 2005-03-17 Siemionow Maria Z. Tolerance induction and maintenance in hematopoietic stem cell allografts
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
CA2655903A1 (en) 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
ES2464815T3 (es) 2007-01-09 2014-06-04 Biogen Idec Ma Inc. Anticuerpos SP35 y usos de éstos
WO2010027797A1 (en) 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
WO2012012737A2 (en) * 2010-07-23 2012-01-26 The University Of Toledo Stable tregs and related materials and methods
UY34317A (es) * 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
MX384246B (es) * 2013-10-30 2025-03-14 Genzyme Corp POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß.

Also Published As

Publication number Publication date
US20160244523A1 (en) 2016-08-25
US11142575B2 (en) 2021-10-12
CN106795220A (zh) 2017-05-31
EP3063174A2 (en) 2016-09-07
MX384246B (es) 2025-03-14
CA2928756A1 (en) 2015-05-07
AU2014342182B2 (en) 2020-05-14
EP3063174B1 (en) 2020-12-09
SG11201603193PA (en) 2016-05-30
AU2020217395A1 (en) 2020-09-03
WO2015066379A3 (en) 2015-07-09
WO2015066379A2 (en) 2015-05-07
AU2014342182A1 (en) 2016-05-19
US20220098299A1 (en) 2022-03-31
SG10201803473WA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
MX2016005687A (es) Metodos para potenciar la terapia inmunosupresora mediante administracion multiple de polipeptido de union a tcr alfa beta.
CL2021001986A1 (es) Anticuerpos y receptores quiméricos de antígenos específicos para receptor 1 huérfano tipo receptor tirosina-cinasa (ror1).
PH12020500677A1 (en) Neoantigens and uses thereof
PH12018500766A1 (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor
CO2020016586A2 (es) Diversos dominios de enlace de antígenos, nuevas plataformas y otras mejoras para terapia celular
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
CR20200014A (es) Molécula de polipéptido con especificidad dual mejorada
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
MX2017012805A (es) Complejo de unión a antígenos con actividad agonista y métodos de uso.
MX387562B (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
MX2020003046A (es) Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.
MX2020007021A (es) Receptor quimerico de antigeno anti-cd19 humanizado.
MX2015014017A (es) Variante de la region fc.
MX393951B (es) Anticuerpos antisortilina y métodos para su uso.
MX374929B (es) RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
EA032960B1 (ru) Антитела, содержащие химерные константные домены
MX2014005108A (es) Constructos de polipeptidos y sus usos.
AR081750A1 (es) Anticuerpos anti-cd40
GB2567093A (en) Histone deacetylase inhibitors for use in immunotherapy
EP4273233A3 (en) Mr1 restricted t cell receptors for cancer immunotherapy
BR112016002401A8 (pt) Métodos para reduzir as taxas de exacerbação de asma usando benralizumab
PH12016501339B1 (en) Novel anti-netrin-1 antibody
EA201691548A1 (ru) Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
HK1227898A1 (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide